<DOC>
	<DOCNO>NCT01566292</DOCNO>
	<brief_summary>The injection botulinum neurotoxin A prostate represent alternative , minimal invasive treatment patient low urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH ) . Objective : To evaluate effectiveness BTA treat patient symptomatic BPH unsatisfactory response combine medical therapy .</brief_summary>
	<brief_title>Intraprostatic Botulinum Toxin Type `` A '' Injection Patients With Benign Prostatic Hyperplasia Unsatisfactory Response Medical Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderatetosevere LUTS determine International Prostate Symptom Score Mean peak urinary flow rate 15 mL/s void volume least 150 mL , postvoid residual urine volume ( PVR ) 100 ml urodynamic parameter indicative bladder outlet obstruction ( BOO ) accord International Continence Society Patients neurogenic voiding disorder , prostate bladder cancer , bladder stone , urethral stricture , chronic bladder catheterization exclude study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>